NED-170 CANCER: Transforming Treatment for Cancer
NED’s comprehensive multi-pronged approach to treating disease began with the development of NED-170 CANCER, an investigational treatment for cancer. Using a well-tolerated, oral dosing regimen, we have observed the potential benefit and lack of severe side effects of NED-170 CANCER in pre-clinical studies and observational patients. NED-170 CANCER holds the promise to not only change long-term outcomes in numerous cancers, but also to radically improve the patient experience during treatment–a philosophy our founder has held ever since her sister’s cancer diagnosis in 2001.
Cancer is a challenging therapeutic target. Therapies based on a single target or biological process typically have a limited efficacy window. Despite all the advancements with today’s “precision medicine” approach, approximately 50% of all late-stage patients do not have the tumor defects addressed by the targeted “matched” drugs. To date, no multi-target therapy approaches have been designed for “unmatched” patients. High toxicity, along with low quality of life and limited survival, is still the experience for many advanced stage cancer patients today.